One of two forms of vitamin B12 that cells use directly. The case is strongest for correcting a genuine shortfall: tablets and lozenges match injections, and the anaemia and nerve symptoms resolve. Above that point the evidence thins quickly. Trial safety matches placebo, yet population data link high blood levels to higher death rates in older adults. (Full Review)

Protocol

Standard maintenance dose

500 to 1,000 µg daily

Tablet or sublingual lozenge; matches the doses tested in the oral and sublingual trials

Repletion of confirmed deficiency

1,000 µg daily for 8 to 12 weeks

Then maintenance; oral and sublingual routes matched intramuscular injection

Best time of day

Morning

Evening dosing is the more likely to disturb sleep onset

Time to effect

Status restored

Days

Serum cobalamin rises within days; methylmalonic acid normalises within 1 to 2 weeks

Anaemia resolved

6 to 8 weeks

Enlarged red cells return to normal size

Neurological recovery

3 to 12 months

May be incomplete after prolonged deficiency

Benefits

High: Correction of vitamin B12 deficiency; improvement of diabetic peripheral neuropathy

Medium: Prevention of capecitabine-induced hand-foot syndrome; relief of shingles-related nerve pain; slowing of functional decline in early motor-neurone disease; homocysteine and LDL cholesterol reduction in methylation-variant carriers

Low: Reduction of stroke risk; support of cognitive function in older adults; improvement of mood and fatigue; alerting and sleep-wake rhythm effects

Speculative: Preservation of methylation capacity across the lifespan

Contraindications

Untreated polycythaemia vera or another myeloproliferative neoplasm, until blood-specialist review

Known cobalt or cobalamin hypersensitivity, including prior anaphylaxis to injectable vitamin B12

Leber hereditary optic neuropathy requiring the hydroxocobalamin form specifically

Serum vitamin B12 above 600 pmol/L that has not been explained, until the cause is identified

Nitrous oxide exposure in untreated deficiency

Key Interactions

Metformin (prescription): monitor

Proton pump inhibitors and H2 blockers (omeprazole, esomeprazole, famotidine): monitor

Colchicine, chloramphenicol and aminosalicylic acid (prescription): caution

Potassium-lowering medications (diuretics such as furosemide; chronic over-the-counter laxatives): monitor

Folic acid and methylfolate (supplement): caution, additive on homocysteine

Potassium supplements, vitamin B6, betaine and creatine (supplements): monitor, additive

Vitamin C in large doses and copper (supplement): caution

Risk & Side Effects

Medium: Accelerated kidney function decline and vascular events on high-dose B-vitamin regimens; higher all-cause mortality at elevated circulating vitamin B12

Low: Acneiform skin eruptions; increased lung cancer incidence in men on long-term high-dose supplements; hypersensitivity reactions to injectable cobalamin; transient hypokalaemia during rapid correction of severe deficiency

Speculative: Aggravation of myeloproliferative disorders; insomnia from evening dosing

Monitoring

Marker	Target	Why
Serum vitamin B12	500-800 pmol/L	Primary status marker
Methylmalonic acid (MMA)	Below 270 nmol/L	Detects tissue-level deficiency that serum vitamin B12 misses
Homocysteine	Below 9 µmol/L	Tracks methylation capacity and combined B-vitamin adequacy
Holotranscobalamin	Above 50 pmol/L	The fraction of circulating vitamin B12 actually deliverable to cells
Serum folate	20-45 nmol/L	Partner nutrient in the same cycle; a deficit blocks the homocysteine response
Complete blood count with mean corpuscular volume (MCV)	MCV 82-89 fL	Detects the enlarged red cells of deficiency and confirms recovery
Potassium	4.0-4.5 mmol/L	Guards against the fall that accompanies rapid red cell production
Thyroid stimulating hormone (TSH)	0.5-2.0 mIU/L	Autoimmune thyroid disease clusters with pernicious anaemia

Cadence: Baseline panel before the first dose; potassium at day 2 and day 7 during rapid repletion of severe deficiency; full panel at 12 weeks; then every 6 to 12 months indefinitely. Annual retesting on long-term metformin or acid-suppressing medication.

Qualitative Assessment

Tingling, numbness or burning in hands and feet, and whether it recedes
Balance in the dark or with eyes closed, which reflects position sense in the spinal cord
Daytime energy and exercise tolerance at a fixed workload
Cognitive clarity, word-finding and short-term recall
Mood stability, and any jitteriness after dosing that would suggest methyl-donor sensitivity
Sleep onset latency, particularly after any change in dose timing
Skin, specifically the appearance of acneiform lesions on face, chest or back

Methylcobalamin for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment